Required role of apoptotic myogenic precursors and toll-like receptor stimulation for the establishment of autoimmune myositis in experimental murine models

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 809-822

  Sciorati, Clara ^a   Monno, Antonella ^a   Ascherman, Dana P ^b   Seletti, Elena ^c   Manfredi, Angelo A ^c   Rovere Querini, Patrizia ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; CARDIOTOXIN; DYSTROPHIN; GLYCEROL; HISTIDINE TRANSFER RNA LIGASE; RESIQUIMOD; AUTOANTIBODY; AUTOANTIGEN; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; APOPTOTIC MYOGENIC PRECURSOR; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOSITIS; CONTROLLED STUDY; IMMUNIZATION; LYMPHOCYTIC INFILTRATION; MOUSE; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOBLAST; MYOSITIS; NONHUMAN; PHENOTYPE; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SATELLITE CELL; ULTRAVIOLET B RADIATION; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; EXPERIMENTAL CNS AUTOIMMUNE DISEASE; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOANTIGENS; BLOTTING, WESTERN; FLOW CYTOMETRY; HISTIDINE-TRNA LIGASE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; TOLL-LIKE RECEPTOR 7;

EID: 84923605605     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38985     Document Type: Article

References (60)

1. Rayavarapu S, Coley W, Kinder TB, Nagaraju K,. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle 2013; 3: 13.
2. Tournadre A, Miossec P,. A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol 2013; 9: 438-42.
3. Venalis P, Lundberg IE,. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) 2014; 53: 397-405.
4. Choi JH, Park YE, Kim SI, Kim JI, Lee CH, Park KH, et al. Differential immunohistological features of inflammatory myopathies and dysferlinopathy. J Korean Med Sci 2009; 24: 1015-23.
5. Hohlfeld R, Engel AG,. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29: 498-507.
6. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R,. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 1995; 181: 1863-8.
7. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97: 9209-14.
8. null T cells. Arthritis Rheum 2010; 62: 3457-66.
9. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013; 15: 335.
10. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56: 3125-31.
11. Mammen AL,. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7: 343-54.
12. Casciola-Rosen L,. Histidyl-transfer RNA synthetase: a key participant in idiopathic inflammatory myopathies [editorial]. Arthritis Rheum 2011; 63: 331-3.
13. Targoff IN,. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000; 12: 475-81.
14. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002; 196: 781-91.
15. Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun 2007; 29: 174-86.
16. Soejima M, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP,. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum 2011; 63: 479-87.
17. Fernandez I, Harlow L, Zang Y, Liu-Bryan R, Ridgway WM, Clemens PR, et al. Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. J Immunol 2013; 191: 1865-72.
18. Suber TL, Casciola-Rosen L, Rosen A,. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008; 4: 201-9.
19. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A,. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60: 3784-93.
20. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
21. Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci 2006; 119: 1824-32.
22. Dhawan J, Rando TA,. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment. Trends Cell Biol 2005; 15: 666-73.
23. McKinnell IW, Parise G, Rudnicki MA,. Muscle stem cells and regenerative myogenesis. Curr Top Dev Biol 2005; 71: 113-30.
24. Relaix F, Zammit PS,. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012; 139: 2845-56.
25. Buckingham M,. Skeletal muscle formation in vertebrates. Curr Opin Genet Dev 2001; 11: 440-8.
26. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000; 204: 64-74.
27. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
28. Vezzoli M, Castellani P, Corna G, Castiglioni A, Bosurgi L, Monno A, et al. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 2011; 15: 2161-74.
29. Rigamonti E, Touvier T, Clementi E, Manfredi AA, Brunelli S, Rovere-Querini P,. Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage. J Immunol 2013; 190: 1767-77.
30. Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, Azzoni E, et al. A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res 2011; 64: 210-7.
31. Sciorati C, Esposito A, Campana L, Canu T, Monno A, Palmisano A, et al. 7-Tesla magnetic resonance imaging precisely and noninvasively reflects inflammation and remodeling of the skeletal muscle in a mouse model of antisynthetase syndrome. Biomed Res Int 2014; 2014: 879703.
32. Casciola-Rosen LA, Anhalt G, Rosen A,. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.
33. Salajegheh M, Lam T, Greenberg SA,. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6: e20266.
34. Ray A, Amato AA, Bradshaw EM, Felice KJ, DiCapua DB, Goldstein JM, et al. Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS One 2012; 7: e46709.
35. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5?-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408-18.
36. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5?-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73: 397-407.
37. Evans J, Levesque D, Shelton GD,. Canine inflammatory myopathies: a clinicopathologic review of 200 cases. J Vet Intern Med 2004; 18: 679-91.
38. Wu X, Li ZF, Brooks R, Komives EA, Torpey JW, Engvall E, et al. Autoantibodies in canine masticatory muscle myositis recognize a novel myosin binding protein-C family member. J Immunol 2007; 179: 4939-44.
39. Casciola-Rosen L, Rosen A, Petri M, Schlissel M,. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1996; 93: 1624-9.
40. Rosen A, Casciola-Rosen L,. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
41. Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159: 5391-9.
42. Albert ML, Sauter B, Bhardwaj N,. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.
43. Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, et al. Remnants of suicidal cells fostering systemic autoaggression: apoptosis in the origin and maintenance of autoimmunity [review]. Arthritis Rheum 2000; 43: 1663-72.
44. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467-71.
45. Bondanza A, Zimmermann VS, Dell'Antonio G, Cin ED, Balestrieri G, Tincani A, et al. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum 2004; 50: 1549-60.
46. Manfredi AA, Sabbadini MG, Rovere-Querini P,. Dendritic cells and the shadow line between autoimmunity and disease [editorial]. Arthritis Rheum 2005; 52: 11-5.
47. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380-4.
48. Baechler EC, Bilgic H, Reed AM,. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13: 249.
49. Rayavarapu S, Coley W, Nagaraju K,. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol 2011; 23: 579-84.
50. Hall JC, Casciola-Rosen L, Rosen A,. Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am 2004; 30: 455-71, vii.
51. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF,. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-70.
52. Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011; 76: 2079-88.
53. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE,. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007; 56: 3112-24.
54. Tournadre A, Lenief V, Miossec P,. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010; 62: 2144-51.
55. Tournadre A, Lenief V, Eljaafari A, Miossec P,. Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2012; 64: 533-41.
56. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-30.
57. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586-94.
58. Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky DS, Harris HE, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010; 24: 570-8.
59. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 2013; 72: 1390-9.
60. Campana L, Santarella F, Esposito A, Maugeri N, Rigamonti E, Monno A, et al. Leukocyte HMGB1 is required for vessel remodeling in regenerating muscles. J Immunol 2014; 192: 5257-64.